Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.76 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110670 | 0.90 | CYP3A4 (0.62) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL4119552 | 0.87 | CASP6 (0.67) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL4107129 | 0.82 | CASP6 (0.77) | FGF1CYP1A2CASP6SIRT1KMT2A | |
| SCHEMBL11900392 | 0.82 | NPC1 (0.71) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL7233377 | 0.82 | CASP6 (0.60) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL10904449 | 0.81 | APEX1 (0.62) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL6240628 | 0.80 | CASP6 (0.72) | FGF1CYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL2747077 | 0.79 | NPC1 (0.71) | CYP3A4NPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL30184438 | 0.78 | NPC1 (1.00) | CYP3A4NPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL4642544 | 0.78 | NPC1 (1.00) | CYP3A4NPC1RAB9ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | claimed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | claimed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | claimed |
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | disclosed |
| EP-1994929-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2008-11-26 | — | — | EP | disclosed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | NQO2, SQLE, SQOR | FGF1 693/4885ALOX5 324/4885CYP3A4 1607/4885 |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | SUCNR1, NR1H4, CYP2B6 | FGF1 1378/4885ALOX5 2834/4885CYP3A4 328/4885 |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | SUCNR1, NR1H4, CYP2B6 | FGF1 1320/4885ALOX5 2925/4885CYP3A4 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.